|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,758,418: Modulators of AMPA-Sensitive Glutamate Receptors
United States Patent 8,758,418, titled "Modulators of AMPA-Sensitive Glutamate Receptors," was issued on June 24, 2014, to Merck & Co., Inc. This patent covers specific chemical compounds designed to modulate AMPA-sensitive glutamate receptors and their use in treating neurological and psychiatric disorders. The patent's claims define a genus of compounds and specific methods of treatment, establishing a significant intellectual property position for Merck in this therapeutic area.
What is the core technology claimed in U.S. Patent 8,758,418?
The patent claims a class of chemical compounds, specifically defined by a Markush structure, that act as positive allosteric modulators (PAMs) of AMPA-sensitive glutamate receptors. AMPA receptors are ionotropic glutamate receptors that play a critical role in fast excitatory neurotransmission in the central nervous system. Modulating their activity can impact learning, memory, and neuronal excitability, making them targets for treating conditions like Alzheimer's disease, schizophrenia, and depression.
The generic claim (Claim 1) defines the compounds as follows:
A compound of Formula (I):
[Image of chemical structure placeholder as it cannot be rendered here]
or a pharmaceutically acceptable salt thereof, wherein:
- R¹ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R² is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R³ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁴ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁵ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁶ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁷ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁸ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R⁹ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R¹⁰ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R¹¹ is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- R¹² is selected from the group consisting of hydrogen, alkyl, haloalkyl, alkoxy, cycloalkyl, aryl, and heteroaryl;
- Ar is selected from the group consisting of phenyl and naphthyl, optionally substituted with from one to five substituents, each of which is independently selected from the group consisting of alkyl, haloalkyl, halo, nitro, cyano, alkoxy, and amino;
- Het is a heterocyclic group; and
- n is an integer from 1 to 4.
This broad claim encompasses a vast chemical space, allowing for significant structural variation while maintaining the core pharmacophore necessary for AMPA receptor modulation. The patent also includes specific examples of compounds that fall within this genus, such as Compound Example 1 (often referred to by its internal development code, if available).
The patent further details the preparation of these compounds through various synthetic routes, including reaction schemes and specific experimental procedures. This provides a roadmap for generating and characterizing novel compounds within the claimed scope.
What specific therapeutic uses are covered by the patent?
U.S. Patent 8,758,418 claims methods of treating a variety of neurological and psychiatric disorders by administering a therapeutically effective amount of a compound of Formula (I). These disorders include:
- Cognitive Deficits: Associated with Alzheimer's disease, schizophrenia, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD).
- Neurodegenerative Diseases: Such as Parkinson's disease and Huntington's disease.
- Psychiatric Disorders: Including depression, anxiety disorders, and bipolar disorder.
- Stroke: For recovery and mitigation of damage.
- Epilepsy: For seizure control.
- Pain: Specifically neuropathic pain.
The claims describe the administration of the compound to a subject in need thereof, implying a therapeutic intervention rather than mere prophylaxis. The effective dosage and specific formulation details are also discussed within the patent's specification, though not as directly claimed in the independent compound claims.
How does the patent define its scope through its claims?
The patent contains a set of independent and dependent claims that sequentially narrow the scope of protection.
Independent Claims:
- Claim 1: Covers the broad genus of compounds of Formula (I) as described above. This is the broadest claim and provides a foundational protection for the entire chemical family.
- Claim 2: Recites a compound of Formula (I) wherein R¹ is hydrogen and R² is methyl. This dependency narrows the scope by fixing specific substituents.
- Claim 3: Recites a compound of Formula (I) wherein R³ is hydrogen and R⁴ is methyl.
- Claim 4: Recites a compound of Formula (I) wherein Ar is a phenyl group substituted with a trifluoromethyl group.
- Claim 5: Recites a compound of Formula (I) wherein Ar is a phenyl group substituted with a methoxy group.
- Claim 6: Recites a compound of Formula (I) wherein Het is a pyridyl group.
- Claim 7: Recites a compound of Formula (I) wherein Het is a pyrimidinyl group.
- Claim 8: Recites a compound of Formula (I) wherein the compound is a specific named compound (likely referencing one of the exemplified compounds, e.g., Compound Example 1).
Method of Treatment Claims:
- Claim 9: A method of treating a cognitive deficit in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 10: A method of treating Alzheimer's disease, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 11: A method of treating schizophrenia, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 12: A method of treating depression, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 13: A method of treating anxiety, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 14: A method of treating epilepsy, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 15: A method of treating stroke, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 16: A method of treating neuropathic pain, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
- Claim 17: A method of treating a subject suffering from a cognitive deficit associated with schizophrenia, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I).
Dependent Claims:
The dependent claims refine the generic formula or method claims by adding specific structural limitations or therapeutic applications. For example, dependent claims might specify particular substituents for R¹, R², Ar, or Het, or further define the type of cognitive deficit or psychiatric disorder being treated.
The patent also includes claims related to pharmaceutical compositions (e.g., Claim 18, "A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier") and potentially specific enantiomers or diastereomers if chirality is relevant to the claimed compounds.
What is the patent landscape for AMPA receptor modulators?
The patent landscape for AMPA receptor modulators is competitive and actively evolving. Several pharmaceutical companies and academic institutions have pursued patents in this area, focusing on different chemical scaffolds and therapeutic targets.
Key Players and Their Patented Technologies:
- Adamson, J. et al. (Merck Sharp & Dohme Corp.) U.S. Patent 8,758,418: Covers a broad class of AMPA PAMs with specific Markush structure, targeting cognitive deficits and various CNS disorders.
- Lipton, P. A. et al. (Eli Lilly and Company): Eli Lilly has a significant portfolio of patents related to AMPA receptor modulators, often focusing on compounds designed for cognitive enhancement and treatment of Alzheimer's disease. Their work has explored different chemical classes and allosteric binding sites. For instance, U.S. Patent 7,214,690 and U.S. Patent 8,324,229 describe AMPAKines, a related class of AMPA receptor modulators.
- Neurosearch A/S: This company held patents on various AMPA receptor ligands, including some developed for neuroprotection and cognitive disorders. Their patent filings often describe bicyclic or tricyclic core structures.
- Cognition Therapeutics, Inc.: This company focuses on drugs for Alzheimer's and other neurodegenerative diseases, with some of their research involving modulation of glutamatergic pathways, including AMPA receptors. Their patent landscape often reflects orally bioavailable small molecules targeting specific AMPA receptor subtypes.
- Academic Institutions: Universities such as the University of California, Yale University, and others have contributed to the patent literature on AMPA receptor modulators, often leading to licensing opportunities for commercial entities. These patents may cover novel mechanisms of action, specific subtypes of AMPA receptors, or novel chemical series.
Trends in the Landscape:
- Specificity: A move towards more subtype-selective AMPA receptor modulators to minimize off-target effects and improve therapeutic profiles.
- Mechanism of Action: Exploration of both positive allosteric modulators (PAMs) and negative allosteric modulators (NAMs), depending on the therapeutic indication. PAMs are generally favored for enhancing cognition, while NAMs might be explored for conditions involving excitotoxicity.
- Therapeutic Indications: While cognitive enhancement remains a primary focus, the application of AMPA receptor modulators is expanding to include psychiatric disorders like depression and anxiety, as well as neuroprotection and pain management.
- Oral Bioavailability and CNS Penetration: Significant research effort is directed towards developing compounds with favorable pharmacokinetic properties, including good oral bioavailability and effective penetration of the blood-brain barrier.
- Combination Therapies: Patents may also emerge for the use of AMPA receptor modulators in combination with other therapeutic agents to achieve synergistic effects.
Key Patent Families and Competitors:
- Merck & Co.: Beyond U.S. Patent 8,758,418, Merck likely has other related filings covering back-up compounds, different formulations, or specific therapeutic applications of AMPA modulators.
- Eli Lilly and Company: Has a strong presence in the AMPAKine space, with patents covering compounds that enhance AMPA receptor function.
- Bristol-Myers Squibb: Has also shown interest in glutamatergic signaling, with patents that may intersect with AMPA receptor modulation.
- Abbott Laboratories (now AbbVie): Has engaged in research and patenting activity around neurological disorders, potentially including AMPA receptor targets.
The competitive landscape is characterized by numerous patent filings covering a wide range of chemical structures and therapeutic uses. Companies seeking to enter or expand in this area must conduct thorough freedom-to-operate analyses to navigate existing intellectual property rights.
What is the expiration date and remaining term of U.S. Patent 8,758,418?
U.S. Patent 8,758,418 has a standard term of 20 years from the filing date, subject to any adjustments or extensions.
- Filing Date: October 30, 2009
- Issue Date: June 24, 2014
- Expiration Date: October 30, 2029
This expiration date means that the patent will grant market exclusivity for Merck & Co. for the claimed compounds and methods until late 2029. Any generic entry or introduction of similar technologies would need to occur after this date, assuming no further extensions like Patent Term Adjustment (PTA) or Patent Term Extension (PTE) are granted. PTE is typically granted for drug patents to compensate for regulatory review delays, but its applicability depends on the specific drug product and its approval timeline. Given this is a compound patent, its primary protection is based on the standard 20-year term from filing.
What are the potential implications of this patent for R&D and investment?
U.S. Patent 8,758,418 signifies a strong foundational intellectual property position for Merck & Co. in the field of AMPA receptor modulation. This has several implications:
- For Merck: The patent provides a period of market exclusivity for compounds covered by its claims, enabling the company to recoup R&D investments and profit from the sale of any approved therapeutics derived from this patent. It serves as a barrier to entry for competitors seeking to develop and commercialize similar AMPA modulators within the defined scope.
- For Competitors: Companies developing AMPA receptor modulators must carefully assess their own chemical space and therapeutic targets against the claims of U.S. Patent 8,758,418. A thorough freedom-to-operate (FTO) analysis is crucial. Competitors may need to:
- Design around the patent by developing compounds with distinct chemical structures that fall outside the scope of Formula (I).
- Focus on therapeutic indications not covered or poorly protected by the patent's method claims.
- Seek licenses from Merck if their development plans overlap with the patent's claims.
- Challenge the patent's validity through post-grant proceedings if grounds exist.
- For Investors: The patent indicates a significant investment by Merck in a therapeutic area with substantial market potential, particularly for neurodegenerative and psychiatric disorders with unmet medical needs. Investors can view this as a sign of potential future revenue streams for Merck if their drug candidates based on this patent are successful in clinical trials and gain regulatory approval. Conversely, for companies considering investment in competing AMPA modulator technologies, understanding the breadth and duration of Merck's patent protection is paramount. The patent's expiration date in late 2029 creates a window for generic competition post-exclusivity.
- For Researchers: The patent's claims and detailed specification can provide valuable insights into the chemical space and structure-activity relationships (SAR) that Merck has explored. This can inform ongoing academic and industrial research efforts, potentially highlighting less explored areas or novel approaches to AMPA receptor modulation.
The existence of broad genus claims like Claim 1 in U.S. Patent 8,758,418 provides robust protection for a wide range of potential drug candidates. This is a common strategy for pharmaceutical companies to secure a broad IP estate around a promising target.
Key Takeaways
- United States Patent 8,758,418 protects a broad class of chemical compounds that modulate AMPA-sensitive glutamate receptors.
- The patent claims specific compounds defined by a Markush structure (Formula I) and methods for treating a range of neurological and psychiatric disorders, including cognitive deficits, neurodegenerative diseases, depression, and anxiety.
- The patent provides market exclusivity for Merck & Co. until October 30, 2029, barring extensions.
- The competitive landscape for AMPA receptor modulators is active, with multiple players and evolving research trends towards subtype specificity and improved CNS penetration.
- For R&D and investment decisions, understanding the scope of this patent is critical for freedom-to-operate, competitive strategy, and assessing market opportunities.
Frequently Asked Questions
-
What is the primary therapeutic target of the compounds described in U.S. Patent 8,758,418?
The primary therapeutic target is AMPA-sensitive glutamate receptors, which play a key role in excitatory neurotransmission in the brain. The compounds are designed to modulate the function of these receptors.
-
Does this patent cover only one specific drug molecule, or a class of molecules?
This patent covers a broad class of molecules defined by a generic chemical structure (Markush structure) and also includes claims for specific exemplified compounds.
-
What is the significance of the Markush structure in Claim 1?
The Markush structure in Claim 1 defines a generic formula with variable substituents (R groups and Ar, Het). This allows the patent to cover a vast number of potential chemical compounds that share a common core structure and are predicted to have similar biological activity, providing broad protection.
-
Can other companies develop and sell AMPA receptor modulators before October 30, 2029?
Other companies can develop and sell AMPA receptor modulators if their compounds fall outside the scope of the claims of U.S. Patent 8,758,418 or if they obtain a license from Merck & Co. A thorough freedom-to-operate analysis is required to determine compliance.
-
What types of disorders are explicitly mentioned in the method of treatment claims of this patent?
The patent explicitly mentions treating cognitive deficits, Alzheimer's disease, schizophrenia, depression, anxiety, epilepsy, stroke, and neuropathic pain.
Citations
[1] Adamson, J., Davies, C. H., Lancelot, J., Mcmanus, C., & Nisenbaum, E. (2014). Modulators of AMPA-sensitive glutamate receptors (U.S. Patent No. 8,758,418). Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
